Fingerprint
Dive into the research topics of 'Phase i dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically